Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma
About this trial
This is an interventional diagnostic trial for GEP-NET
Eligibility Criteria
Inclusion Criteria: Histopathologically verified gastro-entero-pancreatic neuroendocrine neoplasm (GEP-NEN) or patients with unknown primary tumor with metastases with verified NEN positive histopathological examination suggesting GEP origin World Health Organization (WHO) Performance status 0-2 Must be able to read and understand the patient information in Danish and to give informed consent Exclusion Criteria: Pregnancy Breast-feeding Weights more than the maximum weight limit for the PET/CT bed of the scanner (140 kg) Uncontrolled diabetes Uncontrolled infection Exacerbation in autoimmune diseases Other active cancer disease Conditions or diseases (e.g. uncontrolled Parkinson's disease) making the patient unable to lie still in the scanner Severe claustrophobia Localized neuroendocrine neoplasms of the appendix, the rectum measuring < 1 cm, and ECL-omas of the stomach History of allergic reaction attributable to compounds of similar chemical or biologic com-position to 18FDG or 64Cu-DOTATATE
Sites / Locations
- Rigshospitalet
Arms of the Study
Arm 1
Experimental
Experimental
Each patient will undergo one standard of care 18FDG PET/CT and one 64Cu-DOTATATE PET/CT within 4 weeks.